Lone Star Funds Announces Agreement to Acquire the Specialty Chemicals and High Performance Polymers Business Areas of RadiciGroup
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Specialty Chemicals and High Performance Polymers Business Areas of RadiciGroup, a leading global player in the chemical sector.
RadiciGroup, founded in 1941 and headquartered in Bergamo, Italy, is a family-owned company that has established itself as a global leader in the polyamides (nylon) value chain. With an agile business model and a high degree of specialization, RadiciGroup has become a trusted partner serving customers in Europe, the Americas and Asia across the automotive, industrial, electrics/electronics and consumer goods markets.
Lone Star will acquire the Specialty Chemicals and High Performance Polymers Business Areas, while the Radici family will retain control of the Advanced Textiles Solutions Business Area.
“RadiciGroup has a proven track record of innovation, quality and customer commitment, making it a natural addition to Lone Star’s portfolio,” said Donald Quintin, Chief Executive Officer of Lone Star. “This carve-out acquisition is highly complementary to Lone Star’s portfolio of specialty chemicals and manufacturing businesses and aligns well with our strategy of investing in industry leaders with strong growth potential. We are excited to partner with the RadiciGroup team to strengthen competitive positioning, drive operational excellence and unlock new growth opportunities for the business.”
Angelo Radici and Maurizio Radici, President and Vice President of RadiciGroup, also on behalf of the heirs of Paolo Radici, added, “We are very proud of the growth path achieved by RadiciGroup from its foundation until today. The agreement with Lone Star Fundsmarks the beginning of a new chapter in the global expansion of RadiciGroup’s Specialty Chemicals and High Performance Polymers businesses which boast a strong mutual integration. In a constantly evolving market environment, Lone Star Funds’ experience in the chemical sector, combined with its strategic resources and global expertise/reach, will be key factors in supporting the further business growth, while ensuring continued excellence in serving customers. The Radici family will continue to drive the Advanced Textile Solutions Business Area focusing on innovation and sustainability."
The transaction is expected to close in the second half of 2025, subject to customary closing conditions and regulatory approvals.
About Lone Star
Lone Star is a leading private equity firm advising funds that invest globally in corporate equity, credit, real estate and other financial assets. Since the establishment of its first fund in 1995, Lone Star has organized 25 private equity funds with aggregate capital commitments totaling approximately $95 billion. The firm organizes its funds in three series: the Opportunity Fund series; the Commercial Real Estate Fund series; and the U.S. Residential Mortgage Fund series. Lone Star invests on behalf of its limited partners, which include institutional investors such as pension funds and sovereign wealth funds, as well as foundations and endowments that support medical research, higher education, and other philanthropic causes. For more information regarding Lone Star Funds, go to www.lonestarfunds.com.
About RadiciGroup
With 3,000 employees, sales of €1,069 million in 2023, and a network of production units and sales offices across Europe, North and South America, and Asia, RadiciGroup is a global leader in the production of a wide range of chemical intermediates, polyamide polymers, high-performance engineering polymers, and advanced textile solutions. Operating through its three macro Business Areas - Specialty Chemicals, High Performance Polymers and Advanced Textile Solutions - RadiciGroup provides materials for a diverse range of industrial sectors, including automotive, electrics/electronic, consumer goods, clothing, furniture, construction, household appliances, and sport. At the core of the Group’s strategy are innovation, quality, and customer satisfaction, all pursued in alignment with ESG principles. For more information www.radicigroup.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224145829/en/
Contacts
mediarelations@lonestarfunds.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Outpost24 Secures New Investment to Scale its Exposure Management and Identity Security Solutions17.12.2025 09:00:00 EET | Press release
Outpost24, a leader in exposure management and identity security, today announced a new investment from Vitruvian Partners to fuel its next phase of global growth. This significant new funding will accelerate innovation across the company's platform, with a focus on integrating AI capabilities to optimize how security teams identify and neutralize critical vulnerabilities. The only European vendor recognized as an overall leader in the 2025 KuppingerCole Leadership Compass Report for Attack Surface Management, Outpost24 delivers a distinct approach to cyber defence that empowers security teams to gain a complete understanding of their digital and human risk landscape. Last week, Outpost24 announced the acquisition of Infinipoint, a specialist in device identity, posture validation, and secure workforce access. The acquisition marks the company's entry into the Zero Trust Workforce Access market and lays the foundation for its identity security division, Specops, to offer a unified appr
VeritasChain Unveils VAP Architecture, New Auditability Research, and Confirms Submissions to 58 Regulators Globally17.12.2025 09:00:00 EET | Press release
VeritasChain today unveiled its Verifiable AI Provenance Framework (VAP) architecture, published new research on verifiable audit trails, and confirmed informational submissions to 58 regulatory authorities across 43 jurisdictions. These milestones advance VeritasChain’s mission to establish a global framework for verifiable auditability in AI and algorithmic trading. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216433807/en/ Map indicates jurisdictions where regulatory outreach or informational submissions have been made as of Dec 2025. Verifiable AI Provenance Framework (VAP) VAP is a layered assurance architecture designed for independent verification of AI decision-making. It is not a single product, but a framework defining how cryptographic evidence and third-party verification interoperate across diverse systems. The architecture records decision-to-execution events as immutable audit trails, facilitating regulat
New Published Data Confirms Nemluvio ® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis17.12.2025 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements observed as early as 48 hours after treatment in some patients with atopic dermatitis and prurigo nodularis.1 The findings from post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs were published in the Journal of the European Academy of Dermatology and Venereology. Nemolizumab is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signalling of IL-31.2,5,6 IL-31 is a neuroimmune cytokine that drives itch and other symptoms in both atopic dermatitis and prurigo nodularis.3,4 These new findings reinforce the critical role of IL-31 pathway inhibition in achieving rapid itch response. Atopic dermatitis and prurigo nodularis are debilitating skin conditions that significantly affect quality of life, with symptoms such as per
Mori Memorial Foundation’s Global Power City Index 2025 Sees City Rankings Shift Due to Tourism Gains in East Asia and Inflationary Pressures in the West17.12.2025 05:00:00 EET | Press release
The Mori Memorial Foundation’s Institute for Urban Strategies, a research body established by Mori Building, Tokyo’s leading urban landscape developer, today published its annual Global Power City Index (GPCI) 2025, a report evaluating the urban competitiveness of 48 major cities worldwide. The report also includes the GPCI–Financial Centers index, an assessment of cities as international financial centers, and the new GPCI–Startup Ecosystems index, which assesses the competitiveness of startup environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216187692/en/ 48 Major Cities Evaluated in Mori Memorial Foundation’s GPCI-2025 Report This year’s report highlights the remarkable rise of East Asian cities and the stagnation of several Western cities, showing how global challenges, such as geopolitical tensions and regional disparities in inflation, are greatly impacting the performance of major cities worldwide. The r
GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners17.12.2025 04:00:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced it will supply more than 300 CT (computed tomography) scanners under Indonesia’s Strengthening Indonesia’s Health Referral Network (SIHREN) program to deliver equitable, high-quality care to more than 280 million Indonesians. As part of a competitively awarded, multi-year contract, GE HealthCare will supply the advanced CT scanners to public hospitals across all 38 provinces, including urban and remote areas. The CT scanner procurement under SIHREN was conducted through a fully competitive international tender process governed by the World Bank’s procurement regulations. SIHREN is the largest healthcare infrastructure investment in Indonesia’s history and among the largest multilateral health projects globally. SIHREN aims to modernize the national referral system and expand access to diagnostics and treatment across the archipelago, with a focus on non-communicable diseases (NCD) management, maternal health, and pandemic resilience. By mode
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom